Добірка наукової літератури з теми "Minimal pharmacophores"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Minimal pharmacophores".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Minimal pharmacophores":
Mortier, Jérémie, Pratik Dhakal, and Andrea Volkamer. "Truly Target-Focused Pharmacophore Modeling: A Novel Tool for Mapping Intermolecular Surfaces." Molecules 23, no. 8 (August 6, 2018): 1959. http://dx.doi.org/10.3390/molecules23081959.
Petrikaite, Vilma, Eduardas Tarasevišius, and Alvydas Pavilonis. "New ethacridine derivatives as the potential antifungal and antibacterial preparations." Medicina 43, no. 8 (August 11, 2007): 657. http://dx.doi.org/10.3390/medicina43080084.
Spasov, Alexander, Irina Ovchinnikova, Olga Fedorova, Yulia Titova, Denis Babkov, Vadim Kosolapov, Alexander Borisov, et al. "Amino Derivatives of Diaryl Pyrimidines and Azolopyrimidines as Protective Agents against LPS-Induced Acute Lung Injury." Molecules 28, no. 2 (January 11, 2023): 741. http://dx.doi.org/10.3390/molecules28020741.
Mishra, Pranjali, Muskan Srivastav, Yashveer Gautam, Monal Singh, Neeraj Verma, Deepak S. Kapkoti, Shailendra P. Singh, Anil K. Singh, and Devendra P. Rao. "A REVIEW IN CURCUMINOIDS: CHEMISTRY, ANTICANCER ACTIVITY AND FUTURE PROSPECTS." INDIAN DRUGS 61, no. 05 (May 28, 2024): 7–23. http://dx.doi.org/10.53879/id.61.05.14041.
Maatuf, Yossi, Matan Geron, and Avi Priel. "The Role of Toxins in the Pursuit for Novel Analgesics." Toxins 11, no. 2 (February 23, 2019): 131. http://dx.doi.org/10.3390/toxins11020131.
Wermelinger, Guilherme Freimann, Lucas Rubini, Anna Carolina Carvalho da Fonseca, Gabriel Ouverney, Rafael P. R. F. de Oliveira, Acácio S. de Souza, Luana S. M. Forezi, Gabriel Limaverde-Sousa, Sergio Pinheiro, and Bruno Kaufmann Robbs. "A Novel MDM2-Binding Chalcone Induces Apoptosis of Oral Squamous Cell Carcinoma." Biomedicines 11, no. 6 (June 14, 2023): 1711. http://dx.doi.org/10.3390/biomedicines11061711.
Bourne, Yves, Gerlind Sulzenbacher, Laurent Chabaud, Rómulo Aráoz, Zoran Radić, Sandrine Conrod, Palmer Taylor, Catherine Guillou, Jordi Molgó, and Pascale Marchot. "The Cyclic Imine Core Common to the Marine Macrocyclic Toxins Is Sufficient to Dictate Nicotinic Acetylcholine Receptor Antagonism." Marine Drugs 22, no. 4 (March 27, 2024): 149. http://dx.doi.org/10.3390/md22040149.
Caldas Lopes, Eloisi, Shieh Jae-Hung, Srikanth Ambati, Su Tsann-Long, Fabian Correa, Elizabeth Peguero, and Malcolm A. S. Moore. "Novel Alkylating Agent, Ureidomustine Exhibit Pre-Clinical Efficacy in B-Cell Lymphoma with Minimal Dose-Limiting Myelotoxicity." Blood 126, no. 23 (December 3, 2015): 1556. http://dx.doi.org/10.1182/blood.v126.23.1556.1556.
Vawhal, Pallavi Kishor, Shailaja B. Jadhav, Sumit Kaushik, Kahnu Charan Panigrahi, Chandan Nayak, Humaira Urmee, Sharuk L. Khan, et al. "Coumarin-Based Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Pre-ADME Analysis, Toxicity Profile, Computational Analysis, and In Vitro Enzyme Assay." Molecules 28, no. 3 (January 19, 2023): 1004. http://dx.doi.org/10.3390/molecules28031004.
Robertson, Gregory T., Eric J. Bonventre, Timothy B. Doyle, Qun Du, Leonard Duncan, Timothy W. Morris, Eric D. Roche, Dalai Yan, and A. Simon Lynch. "In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Microbiology Profiling Studies with Staphylococci and Streptococci." Antimicrobial Agents and Chemotherapy 52, no. 7 (July 2008): 2324–34. http://dx.doi.org/10.1128/aac.01651-07.
Дисертації з теми "Minimal pharmacophores":
Su, Li. "Generation of analogues of the anti-tumor polyketide stambomycins by genetic engineering and allied approaches." Electronic Thesis or Diss., Université de Lorraine, 2021. http://www.theses.fr/2021LORR0081.
The polyketide secondary metabolites of bacteria are a rich source of bioactive agents, with notable applications in anti-infective and anti-cancer therapy. However, their structures often need to be optimized in order to tailor their therapeutic and biophysical properties. The 51-membered macrolide stambomycins, among the largest of known polyketides, were recently discovered by genome mining in Streptomyces ambofaciens ATCC23877, and notably exhibit promising anti-cancer activity. The family encompasses six members which differ from each other in the alkyl functionality at C-26, due to the alternative choice of extender units by an exceptional acyl transferase domain (AT12) of the modular polyketide synthase (PKS) responsible for synthesizing the stambomycin core. Given their enormous size of the stambomycins and the intrinsic promiscuity of AT12, there is substantial interest in accessing ring-contracted and C-26 substituted derivatives of this compounds which might retain the bioactivity of the parental structures, or exhibit improved or even new properties. In this work, we have leveraged our current understanding of modular PKS systems to internally contract the stambomycin assembly line, leading to the successful generation, albeit at low yield, of target smaller derivatives (37-membered ‘mini-stambomycins’). By careful analysis, we could identify multiple factors contributing to the low titers, information which should inform future engineering strategies. Furthermore, using a mutasynthesis strategy, we were able to exploit the broad specificity of the AT12 domain to create 6 novel C-26 substituted stambomycin analogues. Finally, we unexpectedly identified three series of novel desferrioxamine siderophores produced by S. ambofaciens. As a number of key metabolites generated in this work have potential interest for therapeutic applications, they will be targeted for purification, structural characterization and biological evaluation
Частини книг з теми "Minimal pharmacophores":
Rijkers, Dirk T. S., Jack A. J. den Hartog, and Rob M. J. Liskamp. "Structure-Activity Studies on the Corticotropin Releasing Factor Antagonist Astressin, Minimal Sequence Necessary for Antagonistic Activity: Implications for a New Pharmacophoric Model." In Peptides: The Wave of the Future, 727–28. Dordrecht: Springer Netherlands, 2001. http://dx.doi.org/10.1007/978-94-010-0464-0_339.